HomeMOLN • SWX
add
Molecular Partners AG
Previous close
CHF 4.89
Day range
CHF 4.89 - CHF 4.99
Year range
CHF 3.11 - CHF 9.50
Market cap
200.20M CHF
Avg Volume
20.26K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 681.00K | -73.20% |
Operating expense | 4.41M | -0.38% |
Net income | -16.40M | -43.40% |
Net profit margin | -2.41K | -435.08% |
Earnings per share | -0.49 | — |
EBITDA | -14.00M | -8.64% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 143.62M | -30.49% |
Total assets | 154.21M | -29.30% |
Total liabilities | 15.43M | -29.56% |
Total equity | 138.78M | — |
Shares outstanding | 33.19M | — |
Price to book | 1.17 | — |
Return on assets | -22.46% | — |
Return on capital | -24.30% | — |
Cash Flow
Net change in cash
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -16.40M | -43.40% |
Cash from operations | -13.28M | -0.68% |
Cash from investing | 14.22M | -20.00% |
Cash from financing | -301.00K | -1.01% |
Net change in cash | 66.00K | -98.72% |
Free cash flow | -8.09M | -4.19% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
162
